Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00051142 · ClinicalTrials.gov registry record · Phase 3
A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)
A Phase 3 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00051142: Completed Phase 3 study, sponsored by Alcon Research.
NCT00051142 is a Phase 3 study that has completed, run by Alcon Research. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00051142, a Phase 3 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
The purpose of this study is to evaluate the safety and IOP-lowering efficacy of Travoprost (0.004%) compared to Latanoprost (0.005%) in patients with chronic open-angle glaucoma or ocular hypertension.
Interventions
- DRUG Latanoprost
- DRUG Travoprost
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-02 |
| Est. Completion | 2004-06 |
| Phase | Phase 3 |
What the finished NCT00051142 record still lists
NCT00051142 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which Latanoprost is the first listed.
NCT00051142 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00051142 about?
NCT00051142 is a clinical study titled "A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)". The purpose of this study is to evaluate the safety and IOP-lowering efficacy of Travoprost (0.004%) compared to Latanoprost (0.005%) in patients with chronic open-angle glaucoma or ocular hypertension.
What is the current status of trial NCT00051142?
This trial is currently completed. It is a Phase 3 study. The study started on 2001-02. Estimated completion is 2004-06.
What interventions are being tested in trial NCT00051142?
The interventions under investigation include: Latanoprost (DRUG), Travoprost (DRUG).
Who is sponsoring clinical trial NCT00051142?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia